Genmab A/S (NASDAQ:GMAB) Shares Purchased by Sei Investments Co.

Sei Investments Co. grew its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 55.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 57,702 shares of the company's stock after acquiring an additional 20,525 shares during the quarter. Sei Investments Co.'s holdings in Genmab A/S were worth $1,205,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. EverSource Wealth Advisors LLC increased its stake in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC raised its stake in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC lifted its position in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after acquiring an additional 1,051 shares during the period. Cromwell Holdings LLC grew its stake in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of Genmab A/S in the fourth quarter valued at about $93,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Up 4.4 %

Shares of GMAB stock traded up $0.80 during trading hours on Friday, hitting $18.81. 1,524,787 shares of the company's stock were exchanged, compared to its average volume of 1,018,227. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41. The firm has a market cap of $12.45 billion, a P/E ratio of 10.81, a P/E/G ratio of 2.65 and a beta of 1.07. The firm has a 50 day moving average of $20.48 and a two-hundred day moving average of $21.31.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on GMAB shares. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. Finally, BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.